Analysts Offer Predictions for TERN FY2030 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – HC Wainwright issued their FY2030 EPS estimates for Terns Pharmaceuticals in a research report issued on Wednesday, March 25th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($1.60) per share for the year. HC Wainwright currently has a “Neutral” rating and a $53.00 target price on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share.

TERN has been the topic of several other reports. Citigroup reissued an “outperform” rating on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th. Truist Financial lifted their target price on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen cut Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Oppenheimer upped their price objective on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Finally, UBS Group raised Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $57.33.

Terns Pharmaceuticals Stock Up 5.7%

TERN stock opened at $52.86 on Thursday. Terns Pharmaceuticals has a 52 week low of $1.87 and a 52 week high of $52.98. The stock has a market capitalization of $5.48 billion, a PE ratio of -51.32 and a beta of -0.31. The firm has a 50 day moving average of $40.63 and a 200 day moving average of $28.57.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 14,583 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 170,409 shares of company stock worth $6,563,769. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth about $175,740,000. Seven Fleet Capital Management LP acquired a new stake in shares of Terns Pharmaceuticals in the 4th quarter valued at $1,491,000. Invesco Ltd. raised its stake in Terns Pharmaceuticals by 26.9% in the fourth quarter. Invesco Ltd. now owns 606,247 shares of the company’s stock valued at $24,492,000 after buying an additional 128,573 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth about $215,000. Finally, NewEdge Advisors LLC raised its holdings in Terns Pharmaceuticals by 240.0% during the fourth quarter. NewEdge Advisors LLC now owns 9,173 shares of the company’s stock worth $371,000 after purchasing an additional 6,475 shares in the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

Key Stories Impacting Terns Pharmaceuticals

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to an all-cash acquisition at $53.00 per share, approved by both boards and structured as a tender offer with expected closing in Q2 2026 — the deal provides a clear near-term valuation floor and validates Terns’ lead asset, TERN-701, as strategically valuable to a large pharma buyer. Read More.
• Positive Sentiment: Major media and wire services emphasize the strategic fit (adding a CML allosteric BCR::ABL1 inhibitor) and Merck’s broader push to refill its oncology pipeline ahead of Keytruda’s patent cliff — reinforcing deal rationale for investors. Read More.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $53 price target (essentially aligned with the offer price), suggesting limited upside beyond the transaction price while the deal closes. Read More.
• Neutral Sentiment: Deal mechanics: transaction is a tender offer contingent on shareholder participation and customary closing conditions — market will watch vote/acceptance levels, regulatory review and timing rather than Terns’ standalone clinical milestones. Read More.
• Negative Sentiment: Multiple shareholder-law firms have launched investigations into whether Terns’ board obtained a fair price (Monteverde, Ademi, Halper Sadeh), which could lead to litigation, delay or pressure on deal terms — a risk for timing and transaction certainty. Read More. Read More. Read More.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.